Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis
Quantum BioPharma Ltd. has submitted an Investigational New Drug (IND) application to the FDA for Lucid-MS, a novel therapeutic candidate targeting demyelination in multiple sclerosis (MS). This milestone supports the planned Phase 2 clinical trial aimed at evaluating Lucid-MS's efficacy and safety, representing a significant step forward in Quantu…